Respiratory Disorders and Hospitalization Rates During the Second RSV Season in Preterm Infants Who Received Palivizumab Prophylaxis During Their First RSV Season

REFERENCES

• Kimpen JL, Simoes EA. Respiratory syncytial virus and reactive airway disease. New developments prompt a new review. Am J Respir Crit Care Med 2001; 163 (3 Pt 2): Si.
   Google Scholar
• Ogra PL. Respiratory syncytial virus: The virus, the disease and the immune response. Paediatr Respir Rev 2004; 5 (Suppl A): 5119-126.
   Google Scholar
• Law BJ, Carbonell-Estrany X, Simoes EA. An update on respiratory syncytial virus epidemiology: A developed country perspective. Respir Med 2002; 96 (Suppl B): S1-7.
   Google Scholar
• Bont L, Steijn M, Van Aalderen WM, Brus F, Th Draaisma JM, Van Diemen-Steenvoorde RA, et al. Seasonality of long term wheezing following respiratory syncytial virus lower respiratory tract infection. Thorax 2004; 59 (6): 512–516.
   PubMed Web of Science ®Google Scholar
• Henderson J, Hilliard TN, Sherriff A, Stalker D, Al Sham-man i N, Thomas HM. Hospitalization for RSV bronchiolitis before 12 months of age and subsequent asthma, atopy and wheeze: A longitudinal birth cohort study. Pediatr Allergy Im-munol 2005; 16 (5): 386-392.
   Google Scholar
• Sigurs N. Epidemiologic and clinical evidence of a respira-tory syncytial virus-reactive airway disease link. Am J Respir Crit Care Med 2001; 163 (3 Pt 2): S2-6.
   Google Scholar
• Sigurs N, Gustafsson PM, Bjarnason R, Lundberg F, Schmidt S, Sigurbergsson F, et al. Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13. Am J Respir Crit Care Med 2005; 171 (2): 137–141.
   PubMed Web of Science ®Google Scholar
• Stein RT, Sherrill D, Morgan WJ, Holberg CJ, Halonen M, Taussig LM, et al. Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. Lancet 1999; 354 (9178): 541–545.
   PubMed Web of Science ®Google Scholar
• Bont L, Steijn M, van Aalderen WM, Kimpen JL. Impact of wheezing after respiratory syncytial virus infection on health-related quality of life. Pediatr Infect Dis J 2004; 23 (5): 414–417.
   PubMed Web of Science ®Google Scholar
• The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk in-fants. Pediatrics 1998; 102 (3 Pt 1): 531-537.
   Google Scholar
• Feltes TF, Cabalka AK, Meissner HC, Piazza FM, Carlin DA, Top FH, Jr., et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 2003; 143 (4): 532–540.
   PubMed Web of Science ®Google Scholar
• Simoes EA, Groothuis JR, Carbonell-Estrany X, Rieger CH, Mitchell I, Fredrick LM, et al. Palivizumab prophylaxis, res-piratory syncytial virus, and subsequent recurrent wheezing. J Pe-diatr 2007; 151 (1): 34–42.
   PubMed Web of Science ®Google Scholar
• Medici MC, Arcangeletti MC, Rossi GA, Lanari M, Merolla R, Paparatti UD, et al. Four year incidence of respiratory syncy-tial virus infection in infants and young children referred to emer-gency departments for lower respiratory tract diseases in Italy: the “Osservatorio VRS” Study (2000-2004). New Microbiol 2006; 29 (1): 35–43.
   PubMed Web of Science ®Google Scholar
• Shattuck KE, Abu-Ghosh AM, Wildin SR, Landry SH, Smith KE. Respiratory morbidity in three-year-old children born preterm. Neonatal Intens Care 1998; 11 (1): 11–15
   Google Scholar
• Societa Italiana di Neonatologia. Raccomandazioni per la prevenzione della malattia da virus respiratorio sinciziale (RSV). Riv Ital Pediatr 2000; 26 (3): 379–381
   Google Scholar
• Ruuskanen O, Ogra PL. Respiratory syncytial virus. Curr Probl Pediatr 1993; 23 (2): 50–79.
   PubMedGoogle Scholar
• Campbell A, Pollack P, M. Fredrick L, Groothuis JR. RSV hospitalization rates in preterm children in the season following palivizumab prophylaxis compared to children without palivizumab prophylaxis. Arch Dis Child 2008; 93 (Suppl II): A339-446 [Abstract].
   Google Scholar
• Giovannini M, Rossi GA, Merolla R, Arena F, Cutrera R, Dalla Casa P, et al. Respiratory diseases in infants hospitalized during the 1st 2 years of life for viral lower respiratory tract infections: a one-year follow-up. Minerva Pediatr 2003; 55 (2): 149–155.
   PubMedGoogle Scholar
• Lanari M, Giovannini M, Giuffre L, Marini A, Rondini G, Rossi GA, et al. Epidemiological survey on Italian infants hospitalized with lower respiratory tract infections: role of RespiratorySyncytial Virus. Pediatr Pulmonol 2002; 33: 458–64.
   PubMed Web of Science ®Google Scholar
• Puddu M, Fanos V. Respiratory syncytial virus infection and recurrent wheezing: what next? J Chemother 2007; 19 (Suppl 2): 8–11.
   PubMedGoogle Scholar
• Carbonell-Estrany X, Quero J. Hospitalization rates for respiratory syncytial virus infection in premature infants born dur-ing two consecutive seasons. Pediatr Infect Dis J 2001; 20 (9): 874–879.
   PubMed Web of Science ®Google Scholar
• Carbonell-Estrany X, Quero J, Bustos G, Cotero A, Domenech E, Figueras-Aloy J, et al. Rehospitalization because of respiratory syncytial virus infection in premature infants younger than 33 weeks of gestation: A prospective study. IRIS Study Group. Pediatr Infect Dis J 2000; 19 (7): 592–597.
   PubMed Web of Science ®Google Scholar
• Underwood MA, Danielsen B, Gilbert WM. Cost, causes and rates of rehospitalization of preterm infants. J Perinatol 2007; 27 (10): 614–619.
   PubMed Web of Science ®Google Scholar
• Hall CB, Weinberg GA, [wane MK, Blumkin AK, Edwards KM, Staat MA, Auinger P, Griffin MR, Poehling KA, Erdman D, Grijalva CG, Zhu Y, Szilagyi P. The burden of respiratory syncy-tial virus infection in young children. N Engl J Med 2009; 360 (6): 588–98.
   PubMed Web of Science ®Google Scholar